MX2021014336A - Caracterizacion de variantes de carga especificas del dominio de anticuerpos. - Google Patents

Caracterizacion de variantes de carga especificas del dominio de anticuerpos.

Info

Publication number
MX2021014336A
MX2021014336A MX2021014336A MX2021014336A MX2021014336A MX 2021014336 A MX2021014336 A MX 2021014336A MX 2021014336 A MX2021014336 A MX 2021014336A MX 2021014336 A MX2021014336 A MX 2021014336A MX 2021014336 A MX2021014336 A MX 2021014336A
Authority
MX
Mexico
Prior art keywords
antibodies
domain
specific charge
charge variants
characterization
Prior art date
Application number
MX2021014336A
Other languages
English (en)
Inventor
Michael Rosconi
Erica Pyles
Sophia Liu
Jennifer Nguyen
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2021014336A publication Critical patent/MX2021014336A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/24—Extraction; Separation; Purification by electrochemical means
    • C07K1/26—Electrophoresis
    • C07K1/28—Isoelectric focusing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44756—Apparatus specially adapted therefor
    • G01N27/44795—Isoelectric focusing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/96—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation using ion-exchange

Abstract

La presente invención proporciona métodos y sistemas para analizar las características biofísicas de péptidos o proteínas, tales como anticuerpos, en función de la electroforesis capilar por imágenes asistida por digestión (DiCE) enzimática para caracterizar las variantes de carga específicas del dominio, preferentemente dentro de un anticuerpo biespecífico. Los métodos y sistemas incluyen tratar la proteína con enzimas de digestión para generar componentes de la proteína, reducir o desnaturalizar los componentes y separar los componentes en función de sus puntos isoeléctricos.
MX2021014336A 2019-05-23 2020-05-23 Caracterizacion de variantes de carga especificas del dominio de anticuerpos. MX2021014336A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962852220P 2019-05-23 2019-05-23
PCT/US2020/034429 WO2020237230A1 (en) 2019-05-23 2020-05-23 Characterization of domain-specific charge variants of antibodies

Publications (1)

Publication Number Publication Date
MX2021014336A true MX2021014336A (es) 2022-03-17

Family

ID=71266794

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014336A MX2021014336A (es) 2019-05-23 2020-05-23 Caracterizacion de variantes de carga especificas del dominio de anticuerpos.

Country Status (12)

Country Link
US (1) US20200369720A1 (es)
EP (1) EP3973297A1 (es)
JP (1) JP2022533245A (es)
KR (1) KR20220012263A (es)
CN (1) CN113874720A (es)
AU (1) AU2020279471A1 (es)
BR (1) BR112021023438A2 (es)
CA (1) CA3140717A1 (es)
EA (1) EA202193222A1 (es)
IL (1) IL288197A (es)
MX (1) MX2021014336A (es)
WO (1) WO2020237230A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114577885B (zh) * 2020-12-01 2024-03-29 齐鲁制药有限公司 一种检测重组组合抗体含量比例、电荷异质性和/或等电点的方法
US20230027480A1 (en) * 2021-04-08 2023-01-26 Regeneron Pharmaceuticals, Inc. Measurement of therapeutic proteins co-administered to a subject by lc-mrm-ms assay
US20230296559A1 (en) * 2022-03-18 2023-09-21 Regeneron Pharmaceuticals, Inc. Methods and systems for analyzing polypeptide variants

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2225273B1 (en) * 2007-12-21 2012-05-23 Roche Glycart AG Stability testing of antibodies
CN102308216B (zh) * 2009-02-09 2014-07-09 罗切格利卡特公司 免疫球蛋白糖基化模式分析
FR3003171B1 (fr) * 2013-03-15 2015-04-10 Lab Francais Du Fractionnement Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire
JP5973677B2 (ja) * 2013-10-03 2016-08-23 株式会社島津製作所 質量分析を用いたタンパク質の定量方法
US20170370906A1 (en) * 2016-05-27 2017-12-28 Genentech, Inc. Bioanalytical analysis of site-specific antibody drug conjugates

Also Published As

Publication number Publication date
JP2022533245A (ja) 2022-07-21
EA202193222A1 (ru) 2022-03-10
IL288197A (en) 2022-01-01
WO2020237230A1 (en) 2020-11-26
CA3140717A1 (en) 2020-11-26
US20200369720A1 (en) 2020-11-26
BR112021023438A2 (pt) 2022-01-11
EP3973297A1 (en) 2022-03-30
KR20220012263A (ko) 2022-02-03
AU2020279471A1 (en) 2021-12-09
CN113874720A (zh) 2021-12-31

Similar Documents

Publication Publication Date Title
MX2021014336A (es) Caracterizacion de variantes de carga especificas del dominio de anticuerpos.
WO2020102741A8 (en) Methods and compositions for protein sequencing
Nicolau et al. An in-depth snake venom proteopeptidome characterization: Benchmarking Bothrops jararaca
CR20220552A (es) Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
MY188761A (en) Method of reducing serum levels of fc-containing agents using fcrn antagonists
EA201690299A1 (ru) СТАБИЛИЗАЦИЯ Fc-СОДЕРЖАЩИХ ПОЛИПЕПТИДОВ
ATE495447T1 (de) Peptidantikörperdepletion und anwendung zur probenvorbereitung für massenspektrometrie
MY151330A (en) Systems and method for separating proteins from connective tissue
MX2021011726A (es) Escindasas modificadas, usos de las mismas y kits relacionados.
MX2022011973A (es) Composiciones de proteina anti-vegf y metodos para producir la misma.
MX2020005836A (es) Controles sinteticos para inmunohistoquimica.
MX2022005236A (es) Composiciones y metodos para el tratamiento de la perdida auditiva neurosensorial mediante el uso de sistemas de vectores duales de otoferlina.
EA202092088A1 (ru) Антитела анти-phf-тау и их применение
WO2022024024A3 (en) Proteins comprising hla-g antigen binding domains and their uses
WO2021236716A3 (en) Methods, systems and kits for polypeptide processing and analysis
MX2021008590A (es) Metodos para caracterizar enlaces de disulfuro.
CR20200642A (es) Proteínas inmunodominantes y fragmentos en esclerosis múltiples
MX2019013523A (es) Proteínas de fusión de folistatina-fc recombinante y uso en el tratamiento de la distrofia muscular de duchenne.
MX2022003432A (es) Metodos y composiciones que comprenden un anticuerpo monoclonal antictla4 con proteinas de celulas hospederas reducidas y estabilidad del polisorbato-80 aumentada.
MX2020001818A (es) Isoelectroenfoque capilar con imagenes para analizar variantes de proteina en una matriz de muestra.
MX2022014938A (es) Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de éstas.
MX2022010467A (es) Enzimas para la sialilación de glicanos.
PH12021551150A1 (en) Transmembrane domain derived from human lrrc24 protein
IL299757A (en) SARS-COV-2 proteins, antibodies against SARS-COV-2, and methods of using them
MX2020012016A (es) Sistemas y metodos para cuantificar y modificar la viscosidad de proteinas.